FULC

Business Context and Reporting Period

Company: Fulcrum Therapeutics, Inc. (FULC)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Fulcrum is a clinical-stage biopharmaceutical company developing small molecules for genetically defined rare diseases. Its lead product candidate, pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) for the treatment of sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial in 2025 and plans to initiate a potential registration-enabling trial in the second half of 2026 pending FDA feedback. The company discontinued its losmapimod program for facioscapulohumeral muscular dystrophy (FSHD) following a failed Phase 3 trial in 2024.

Key Financial Metrics

Note: 2024 revenue consisted of an $80.0 million upfront payment from a collaboration with Sanofi, which was terminated in 2025 following the failure of the losmapimod Phase 3 trial.

Material Changes vs. Prior Period

• Revenue Decline: Revenue dropped from $80.0 million in 2024 to $0 in 2025 due to the termination of the Sanofi collaboration agreement and the lack of product sales.
• Increased Net Loss: Net loss widened significantly to $74.9 million in 2025 from $9.7 million in 2024, primarily driven by the absence of the $80.0 million collaboration revenue recognized in the prior year.
• Expense Reductions: Total operating expenses decreased by $17.1 million year-over-year. R&D expenses fell by $7.3 million, largely due to the suspension of the losmapimod program and reduced headcount. G&A expenses decreased by $7.8 million due to lower professional services and employee compensation costs.
• Liquidity Improvement: Cash and marketable securities increased by approximately $111.3 million to $352.3 million, bolstered by $164.2 million in net proceeds from a December 2025 public offering of common stock and pre-funded warrants.

Guidance, Outlook, and Risks

Outlook and Guidance

• Cash Runway: Management believes current cash resources ($352.3 million as of Dec 31, 2025) are sufficient to fund operating expenses and capital expenditures into 2029.
• Clinical Timeline: The company plans to provide details on the design of the next trial for pociredir in Q2 2026 following an End-of-Phase meeting with the FDA. A potential registration-enabling trial is targeted for initiation in the second half of 2026.
• Profitability: The company expects to incur significant operating losses for the foreseeable future and may never achieve profitability.

Risks and Contingencies

• Capital Needs: Substantial additional funding will be required. Failure to raise capital could force delays or elimination of product development programs.
• Clinical Development Risk: Pociredir is an EED inhibitor; the FDA previously placed a clinical hold in 2023 due to hematological malignancies observed in toxicology studies (lifted in August 2023). Safety monitoring remains critical.
• Regulatory Uncertainty: Approval is not guaranteed. The company relies on orphan drug and fast-track designations, which do not assure approval.
• Intellectual Property: The company relies on in-licensed patents (e.g., from CAMP4) and its own portfolio. Challenges to patent validity or scope could harm commercial prospects.
• Section 382 Limitations: An ownership change in September 2024 limited the utilization of pre-change net operating loss (NOL) carryforwards, which were written off. Future utilization of NOLs may be restricted by further ownership changes.

Key Facts for Investor Verification

• Cash Position: Verify the $352.3 million cash balance and the specific composition of marketable securities to assess liquidity stability.
• Pociredir Safety Data: Review the full safety profile from the PIONEER trial, specifically regarding hematological malignancies, given the prior FDA clinical hold.
• Sanofi Termination: Confirm that no further payments or liabilities remain from the terminated Sanofi agreement regarding losmapimod.
• Capital Raise Terms: Review the terms of the December 2025 offering (11.85 million shares + pre-funded warrants) for dilution impact and any specific covenants.
• Section 382 Study: Monitor for updates on the Section 382 ownership change study post-December 2024 to understand the usable value of remaining NOLs and tax credits.
• Upcoming Milestones: Track the Q2 2026 FDA meeting minutes and the subsequent initiation of the registration-enabling trial in H2 2026.